Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – AUDIO

Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – VIDEO

The importance of balancing AI and people in drug development

Two CEOs discuss bracing for tariffs, NIH grant cuts and gifting China biopharma leadership position

As biopharma investments stumble, med tech surges

Mega money well spent? Mammoth mergers fall short of the dream

Healing the health divide for women

Modifi gets creative on the rocky road to a multibillion-dollar buyout

A quantum leap into the future of drug development

Gene and cell therapies will propel innovation, says Astellas CCO

Capricor’s CEO pursues a BLA and talks rare disease

The first half of 2024 was strong as M&As and financings dominate

The cost of delays in development and sales: It’s probably not what you think

ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

Fibrobiologics walks the unconventional financing path

Back to fundamentals: The latest numbers point to better times

Mark McKenna storms back with Mirador and eyes the development landscape

Biopharma execs seek to avoid pain points in AI integration

Six biopharma executives consider a tough 2023 and are hopeful for a better 2024

AI: driving drug development from effective to remarkable